471 patents
Page 21 of 24
Utility
Oligonucleotide Compositions and Methods of Use Thereof
17 Jun 20
Among other things, the present disclosure provides designed PNPLA3 oligonucleotides, compositions, and methods thereof.
Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Luciano Henrique Apponi, Hanna Maria Wisniewska, Xiayun Cheng, Young Jin Cho
Filed: 31 May 18
Utility
Diacylglycerol Acyl Transferase 2 Inhibitors
10 Jun 20
Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
Filed: 17 Feb 20
Utility
Process for Preparing Pneumococcal Polysaccharide-protein Conjugates
10 Jun 20
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described.
William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
Filed: 18 Feb 20
Utility
Chemical Compounds
3 Jun 20
Ariamala Gopalsamy, Arjun Venkat Narayanan, Agustin Casimiro-Garcia, Chulho Choi, David Hepworth, David Walter Piotrowski, Hatice Gizem Yayla, Jayasankar Jasti, Lee Richard Roberts, Lyn Howard Jones, Mihir Dineshkumar Parikh, Ming Zhu Chen, Olugbeminiyi Omezia Fadeyi, Ralph Pelton Robinson, JR., Robert Lee Dow, Shawn Cabral
Filed: 25 Nov 19
Utility
PYRAZOLO[1,5-A]PYRAZIN-4-YL and Related Derivatives
3 Jun 20
Brian Stephen Gerstenberger, Andrew Fensome, Dafydd Rhys Owen, Matthew Frank Brown, Matthew Merrill Hayward, Felix Vajdos, Li Huang Xing, Stephen Wayne Wright
Filed: 8 Aug 18
Utility
Azalactam Compounds as HPK1 Inhibitors
3 Jun 20
Rebecca Anne Gallego, Sajiv Krishnan Nair, Robert Steven Kania, Omar Khaled Ahmad, Ted William Johnson, Jamison Bryce Tuttle, Mehran Jalaie, Michele Ann McTigue, Dahui Zhou, Matthew L. Del Bel, Ru Zhou, Mingying He
Filed: 10 Nov 19
Utility
Compositions and Methods Relating to a Mutant Clostridium Difficile Toxin
27 May 20
In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B.
Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G.K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
Filed: 4 Dec 19
Utility
Neisseria Meningitidis Compositions and Methods Thereof
27 May 20
In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide.
Kathrin Ute Jansen, Annaliesa Sybil Anderson, Judith Absalon, Jose Miguel Aste-Amezaga, Johannes Frederik Beeslaar, David Cooper, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Thomas Richard Jones, Isis Kanevsky, Lakshmi Khandke, Paul Liberator, John Lance Perez, Lynn Marie Phelan, Gary Warren Zlotnick
Filed: 4 Dec 19
Utility
6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE Dopamine D3 Ligands
20 May 20
Thomas Allen Chappie, Jaclyn Louise Henderson, Joseph Michael Young, Travis T. Wager, Bethany Lyn Kormos, Nandini Chaturbhai Patel, Simone Sciabola, Jamison Bryce Tuttle, Patrick Robert Verhoest, Joseph Walter Tucker
Filed: 22 Jan 20
Utility
ANTI-ROBO2 Antibodies, Compositions, Methods and Uses Thereof
20 May 20
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.
Stephen Berasi, Janet Elizabeth Buhlmann, Eric M. Bennett, Nathan Higginson-Scott, Huilan Gao, Zong Sean Juo, Stefano V. Gulla, Christine Huard, Sreekumar R. Kodangattil, Jian Li, Weining Lu, Xueping Fan, David J. Salant
Filed: 7 Jun 18
Utility
Substituted 3-AZABICYCLO[3.1.0]HEXANES As Ketohexokinase Inhibitors
13 May 20
Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
Filed: 15 Jan 20
Utility
Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
6 May 20
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Gary W. Zlotnick, Leah D. Fletcher, John E. Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
Filed: 6 Jan 20
Utility
Sodium Chloride Solution for Drug Reconstitution or Dilution
6 May 20
The invention provides methods for preparing pharmaceutical formulations for injection such that upon injection the formulation does not cause erythrocyte agglutination, hemolysis, and/or cell shrinkage.
Chandra A. Webb, Julie Zerfas
Filed: 19 Dec 19
Utility
Manufacturing Process and Intermediates for a PYRROLO[2,3-D]PYRIMIDINE Compound and Use Thereof
22 Apr 20
The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide.
Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane
Filed: 2 Jul 19
Utility
Neisseria Meningitidis Composition and Methods Thereof
22 Apr 20
In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof.
Annaliesa Sybil Anderson, Susan Kay Hoiseth, Kathrin Ute Jansen, Justin Keith Moran, Mark Edward Ruppen
Filed: 12 Dec 19
Utility
Bispecific Antibodies
22 Apr 20
The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and.
Eric M. Bennett, Nathan Higginson-Scott, Lioudmila Tchistiakova, Kimberly A. Marquette, Janet E. Paulsen, Ruth E. Gimeno
Filed: 25 Jun 19
Utility
Boron Containing PDE4 Inhibitors
8 Apr 20
Joseph Walter Strohbach, Tsutomu Akama, David Clive Blakemore, Robert Toms Jacobs, Peter Jones, David Christopher Limburg, Martins Sunday Oderinde, Matthew Alexander Perry, Jacob John Plattner, Rubben Federico Torella, Yasheen Zhou, Thean Yeow Yeoh
Filed: 3 Oct 19
Utility
Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
1 Apr 20
Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
Filed: 3 Dec 19
Utility
ANTI-CXCR4 Antibodies and Antibody-drug Conjugates
1 Apr 20
The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4).
Shu-Hui LIU, Flavia Mercer PERNASETTI, Wei-Hsien HO
Filed: 7 Aug 19
Utility
Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same
25 Mar 20
The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of pemetrexed; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.
Stephen E. Zale
Filed: 8 Dec 19